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Abstract
Background: HIV-1 acute infection, recent infection and transmitted drug resistance screening was integrated into
voluntary HIV counseling and testing (VCT) services to enhance the existing surveillance program in San Francisco. This
study describes newly-diagnosed HIV cases and characterizes correlates associated with infection.
Methodology/Principal Findings: A consecutive sample of persons presenting for HIV VCT at the municipal sexually
transmitted infections (STI) clinic from 2004 to 2006 (N=9,868) were evaluated by standard enzyme-linked immunoassays
(EIA). HIV antibody-positive specimens were characterized as recent infections using a less-sensitive EIA. HIV-RNA pooled
testing was performed on HIV antibody-negative specimens to identify acute infections. HIV antibody-positive and acute
infection specimens were evaluated for drug resistance by sequence analysis. Multivariable logistic regression was
performed to evaluate associations. The 380 newly-diagnosed HIV cases included 29 acute infections, 128 recent infections,
and 47 drug-resistant cases, with no significant increases or decreases in prevalence over the three years studied. HIV-1
transmitted drug resistance prevalence was 11.0% in 2004, 13.4% in 2005 and 14.9% in 2006 (p=0.36). Resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTI) was the most common pattern detected, present in 28 cases of
resistance (59.6%). Among MSM, recent infection was associated with amphetamine use (AOR=2.67; p,0.001), unprotected
anal intercourse (AOR=2.27; p,0.001), sex with a known HIV-infected partner (AOR=1.64; p=0.02), and history of
gonorrhea (AOR=1.62; p=0.03).
Conclusions: New HIV diagnoses, recent infections, acute infections and transmitted drug resistance prevalence remained
stable between 2004 and 2006. Resistance to NNRTI comprised more than half of the drug-resistant cases, a worrisome
finding given its role as the backbone of first-line antiretroviral therapy in San Francisco as well as worldwide. The
integration of HIV-1 drug resistance, recent infection, and acute infection testing should be considered for existing HIV/STI
surveillance and prevention activities, particularly in an era of enhanced efforts for early diagnosis and treatment.
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Introduction
HIV-1 acute infection, recent infection and antiretroviral (ARV)
drug resistance are of clinical and public health significance. Acute
infection is defined as the time interval between the acquisition of
HIV infection and seroconversion. The high viral load during this
stage of infection increases biological transmissibility [1,2]. Risk of
transmission during acute infection is 8–22 times greater on a per-
act basis than later stages of infection [2,3]. In addition, most
persons with acute infection are unaware of their status and may
engage in risky behaviors that enable further transmission [2,4].
Identification of persons with recent infections after the acute
period, e.g., through laboratory-based testing algorithms, may
help track the leading edge of the HIV epidemic within the
community by distinguishing newly-transmitted infections from
newly-diagnosed but long-term infections [5]. The transmission of
drug-resistant strains has been documented, which can potentially
impact virologic, immunologic and broader health outcomes by
decreasing the effectiveness of antiretrovirals [6–9].
Sexually transmitted infections (STI) clinic patients are a
sentinel population used for HIV surveillance worldwide based
on the rationale that high numbers of persons newly infected with
HIV may first present at such facilities since the behaviors that
place individuals at risk for acquiring STI and HIV are similar
[10]. The manifestly high risk for HIV among STI clinic patients
also argues in favor of screening for recent infection among
persons who are HIV-RNA positive/antibody-positive (RNA+/
Ab+) and for acute infection among persons who are HIV-RNA
positive/antibody-negative (RNA+/Ab2). HIV-1 drug resistance
testing can also be integrated into the screening algorithm at STI
clinics to enhance existing surveillance efforts. From 2004 to 2006,
testing for HIV acute infection and transmitted drug resistance
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program of San Francisco’s sole municipal STI clinic. This study
describes the prevalence of HIV-1 transmitted drug resistance,
acute infection, and recent infection and characterizes their
associated correlates.
Methods
Ethics Statement
The study received approval from the Institutional Review
Board at the University of California, San Francisco. No
additional data were collected for this public health surveillance
activity; therefore, written patient consent was not required.
Study Population
A consecutive sample of persons presenting for confidential HIV
VCT at the San Francisco municipal STI clinic from January
2004 to December 2006 (N=9,868) were evaluated. Newly-
identified HIV cases were considered to be ARV treatment-naı ¨ve
since the study population was comprised of testers seeking to
know their HIV status.
Testing Algorithm
Specimens were screened using standard enzyme-linked immu-
noassays (EIA) (Vironostika HIV-1 Microelisa, bioMe ´rieux,
Durham, NC) and OraQuick Rapid Test (OraQuick Advance
HIV 1/2 Antibody Test, Bethlehem, PA). Antibody-positive
samples were confirmed using immunofluoresence assays (Fluor-
ognost HIV-1 IFA, Sanochemia Pharmazeutika AG, Neufeld,
Vienna, Austria). HIV Ab+ specimens were characterized as
recent HIV infections using a testing approach referred to as
‘‘STARHS’’, which stands for ‘‘Serological Testing Algorithm for
Recent HIV Seroconversion’’. STARHS distinguishes recent from
long-term infections using two EIA: a standard assay (Vironostika
HIV-1) that is sensitive to low levels of HIV antibody and a less-
sensitive one (Vironostika-LS) that classifies recent infection using
a 170 day window period [95% CI: 145, 200 days] and an optical
density cut-off value of 1.0 [5]. HIV Ab- specimens were screened
using a quantitative HIV-1 RNA assay with an analytic sensitivity
down to 75 copies/ml (Versant HIV 3.0, Bayer Diagnostics,
Emeryville, CA). Initially, a two-stage pooling strategy was
applied, with a 50 specimen master pool and 10 specimen
intermediate pools. A revised strategy with 10 specimens in each
master pool, followed by individual testing of specimens in any
positive pools was used to expedite turn-around time for results.
Newly-detected HIV infections (RNA+/Ab+ and RNA+/Ab2)
were evaluated for drug resistance by viral genotype population
sequencing (TRUGENE HIV-1 Genotyping Kit, Bayer Diagnos-
tics, Emeryville, CA). The assay detects mutations in the protease
and reverse transcriptase sequences of the HIV-1 genome that
confer resistance to ARVs. Viral genotypic sequencing was
performed on 370 HIV+ specimens and interpretable sequences
were generated for 348 specimens, yielding a 94% assay success
rate. Sequencing results were interpreted using guidelines from the
manufacturer (Version 12 Rules), IAS-USA, and the Stanford
University HIV-1 Drug Resistance Surveillance Program [11,12].
Data Collection
Demographic characteristics and risk behavior information
were obtained from standardized intake data collection forms that
were administered by test counselors in private settings as a routine
part of HIV VCT services. Correlates of acute and recent HIV
Table 2. Distribution of HIV-1 drug-resistant cases by drug
class, San Francisco, 2004–2006.
2004 2005 2006
n% n% n%
Any Drug Class 15 100 15 100 17 100
NRTI 5 33.3 4 26.7 5 29.4
NNRTI 11 73.3 8 53.3 9 52.9
PI 3 20.0 3 20.0 8 47.1
Dual-Class 3 20.0 1 6.7 1 5.9
Multi-Class 0 0.0 0 0.0 2 11.8
NRTI=nucleoside reverse transcriptase inhibitors.
NNRTI=non-nucleoside reverse transcriptase inhibitors.
PI=protease inhibitors.
doi:10.1371/journal.pone.0025281.t002
Figure 1. Temporal trends of HIV cases, San Francisco, 2004–2006.
doi:10.1371/journal.pone.0025281.g001
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analysis of existing data. Data available for analysis included
demographic characteristics (e.g., gender, age, racial/ethnic
identification, sexual orientation), sexual behavior (e.g., gender
of sex partners, number of sex partners, engaging in unprotected
sexual intercourse, and sex with a known HIV-infected partner
within the past twelve months), substance use (e.g., use of injection
drugs, non-injection drugs, and alcohol within the past twelve
months), and medical history (e.g., perceived HIV status before the
current test, number of previous HIV tests, and STD history
within the past two years).
Analysis
HIV infection, recent infection, acute infection, and drug
resistance were compared across years. HIV infection cases
included all persons who were either antibody positive by standard
antibody testing or who were acutely infected. Stages of HIV
infection were defined as follows: (i) acute infections were RNA+/
Ab2, (ii) recent infections were RNA+/Ab+ and transmission
likely occurred within the past 170 days, and (iii) long-term
infections were RNA+/Ab+ and transmission likely occurred
beyond the past 170 days. HIV-1 drug resistance was defined as
having a single major mutation or several minor mutations known
to confer intermediate or high levels of resistance to ARVs. HIV-1
incidence estimates were calculated by dividing the number of
persons with recent infection by persons at risk (recently infected
plus uninfected) and annualized using the following formula: crude
incidence x [(365 days/170 days) x 100%] [4]. For the analysis,
cases of HIV infection, recent infection, and acute infection were
compared to HIV-negative cases. Only HIV-infected persons were
included in the analysis to assess the predictors of drug resistance.
Logistic regression models were fitted to identify independent
predictor variables for the HIV outcomes of recent infection, acute
infection, and drug resistance and to adjust for confounding
factors. Candidate variables were first evaluated by bivariate
analysis. Initial variable selection for the multivariate model was
based on a p-value cut-off of 0.20 for inclusion. Backward
elimination was used for final model selection using a p-value of
0.10 for retention. Ninety-five percent confidence intervals
computed on the odds ratios were derived from the coefficients
and their respective standard errors. Temporal trends were
assessed using the Cochran-Armitage test.
Results
The HIV VCT population consisted of 3,789 testers in 2004,
2,921 testers in 2005, and 3,158 testers in 2006. Testers were
84.4% male, 14.1% female, and 1.3% transgender. By age, 18.1%
were under 25 years old, 41.1% were 25–34, 27.6% were 35–44,
and 13.0% were 45 and older. The testing population was
comprised of 54.4% whites, 20.0% Latinos, 10.6% African-
Americans, 11.8% Asian/Pacific Islanders, and 3.0% other/mixed
race. Risk exposure data were available for 93.8% of testers
(n=9,380), of which 73.1% were men who have sex with men
(MSM), 23.6% were heterosexual, 1.9% were injection drug users
(IDU), and 1.4% were transgender. Among all testers, 36.2%
reported unprotected anal sex (UAI), 16.9% had sex with a known
HIV-positive partner, 11.7% used amphetamines, 4.1% used
injection drugs, 14.7% had a history of gonorrhea, 9.5% had a
history Chlamydia, and 3.2% had a history of syphilis.
There were 380 HIV infections newly diagnosed between 2004
and 2006. Newly-identified HIV cases comprised of 223 long-term
infections (58.7%), 128 recent infections (33.7%), and 29 acute
infections (7.6%). Eleven of the 29 acute infection specimens were
originally screened by the rapid test. Table 1 presents HIV cases
stratified by demographic characteristics, risk exposure categories,
and predictors of risk. HIV prevalence was highest among men
(4.34%), 35–44 year olds (4.78%), African-Americans (4.89%), and
MSM (4.78%), with regards to the proportion of cases relative to
testers with the same demographic characteristics and risk
exposure categories. Acute infections were mainly detected in
testers who were MSM (93.1%), white (44.8%), and 35–44 year
old (34.2%). Recent infection cases were primarily testers who
were MSM (85.9%), white (53.9%), and 25–34 year old (37.5%).
Prevalence of HIV-1 transmitted drug resistance was 13.0%
overall during the three year period. A total of 47 drug-resistant
cases were identified, 77% of which were detected in MSM.
Table 2 shows the distribution of cases by drug class. Mutations
conferring resistance to non-nucleoside reverse transcriptase
inhibitors (NNRTI) were the most common pattern observed.
NNRTI resistance was present in 28 of 47 cases (59.6%),
Figure 2. Temporal trends of HIV cases among men who have sex with men, San Francisco, 2004–2006.
doi:10.1371/journal.pone.0025281.g002
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cases (29.8%), and protease inhibitors (PI) resistance in 14 cases
(29.8%). There were 5 cases of dual-class resistance (2 NRTI/
NNRTI cases, 2 NNRTI/PI cases, 1 NRTI/PI case) and 2 cases
of multi-class resistance (NRTI/NNRTI/PI). The most commonly
detected mutations conferring resistance to NRTI were M184V
(10.6%), K219Q (10.6%), D67N (8.5%), L210W (8.5%), and
M41L (8.5%). The most common resistant mutations to NNRTI
were K103N (36.2%), Y181C (8.5%), and V108I (8.5%) and to PI
were L90M (14.9%), V77I (10.6%), and D30N (6.4%).
The characteristics of HIV cases are presented in Table 1.
Unprotected anal intercourse (UAI) in the past 12 months was
reported by 60.5% of long-term infections, 68.8% of recent
infections, 44.8% of acute infections, and 57.4% of ARV drug-
resistant cases. Sex with a known HIV-infected partner was
reported by 33.6% of long-term infections, 41.4% of recent
infections, 27.6% of acute infections and 27.7% of ARV drug-
resistant cases. Amphetamine use was reported by 27.8% of long-
term infections, 41.4% of recent infections, 27.6% of acute
infections, and 25.5% of ARV drug-resistant cases. Injection drug
use was reported by 3.6% of long-term infections, 7.8% of recent
infections, and 4.3% of ARV drug-resistant cases. A history of
gonorrhea was reported by 23.3% of long-term infections, 25.8%
of recent infections, 31.0% of acute infections, and 27.7% of ARV
drug-resistant cases.
There were no significant temporal trends among all testers in
the prevalence of HIV infection (p=0.74), acute infection
(p=0.80), and HIV incidence (p=0.66), as shown in Figure 1.
When the analyses were limited to MSM, there was a significant
temporal trend in the prevalence of HIV infection (p=0.01) but
not for acute infection (p=0.90) and HIV incidence (p=0.94), as
presented in Figure 2. Reported UAI increased significantly, from
35% in 2004 to 39% in 2006 among all testers (p=0.002) and
from 41% in 2004 to 46% in 2006 among MSM (p,0.001).
Prevalence of HIV-1 transmitted drug resistance did not
decrease over the three year period among all testers (p=0.36)
and MSM (p=0.39), as shown in Figures 1 and 2. There was an
increase in the proportion of cases with PI resistance (p=0.05) and
a borderline increase in multi-class resistance (p=0.07); however,
there was no trend in NNRTI resistance (p=0.94) and dual-class
resistance (p=0.36), as shown in Table 2.
Predictors of elevated risk for recent infection for all testers
included male gender (AOR=5.86 [95% CI: 1.84, 18.62];
p=0.003), amphetamine use (AOR=2.50 [95% CI: 1.70, 3.69];
p,0.001), sex with a known HIV-positive partner (AOR=2.12
[95% CI: 1.47, 3.06]; p,0.001), UAI (AOR=2.01 [95% CI: 1.40,
2.92]; p,0.001), African-American race/ethnicity (AOR=1.88
[95% CI: 1.16, 3.05]; p=0.01), and history of gonorrhea
(AOR=1.45 [95% CI: 0.97, 2.19]; p=0.07). Asian/Pacific
Islander race/ethnicity was protective for recent infection
(AOR=0.40 [95% CI: 0.17, 0.91]; p=0.02). There were no
significant correlates of acute infection or drug resistance.
Separate analyses were conducted for MSM, a risk group that
accounted for 86.3% of HIV infection cases diagnosed. When
analyses were restricted to MSM, recent infection was associated
with amphetamine use (AOR=2.67; p,0.0001), UAI
(AOR=2.27; p=0.0002), sex with a known HIV-infected partner
(AOR=1.64; p=0.02), and history of gonorrhea (AOR=1.62;
p=0.03). Asian/Pacific Islander race/ethnicity (AOR=0.41;
p=0.03) was associated with a lower risk for recent infection,
while sex with an HIV-infected partner (AOR=0.38; p=0.03)
was associated with a lower risk for drug resistance. Bivariate and
multivariate risk models for MSM are detailed in Table 3.
Discussion
New HIV diagnoses, recent infections, acute infections, and
transmitted drug resistance prevalence remained stable between
2004 and 2006. Slightly more than half of newly-diagnosed HIV
cases were long-term infections, one-third were recent infections and
close to one-tenth were acute infections. Nearly all acute and recent
infection cases were detected in MSM. This result is most likely a
reflection of high levels of repeat HIV testing in this population. A
recent survey found 97% of MSM in San Francisco had ever tested
and 34% had tested in the last 6 months [13]. Some studies have
suggested that transmission by acutely-infected cases may account for
25–50% of recently-acquired infections [14,15]. Testing for acute
infection enhanced case detection by 7.6% and enabled referral for
early care and potentially decreased risk of secondary transmission as a
result of awareness of one’s acute infection status.
Prevalence of transmitted HIV-1 drug resistance did not decrease
over the three years studied. The majority of drug-resistant cases were
detected in MSM and more than one-third of the cases reported
having an STI within the past two years. In 85% of the resistant cases,
resistance was limited to a single drug class. Resistance to NNRTI was
the most common pattern observed, comprising more than half of the
cases. The high proportion of cases with resistance to NNRTI is
comparable to the national pattern reported by the U.S. Centers for
Disease Control and Prevention [16]. The finding that a high
proportion of resistant cases were associated with NNRTI mutations
suggests that these mutations may be more common in source partners
or more fit for transmission than other forms of drug-resistant HIV-1.
The lack of a decrease in NNRTI resistance is particularly worrisome
given that this drug class is the backbone of first-line antiretroviral
therapy in San Francisco as well as worldwide, according to the
recommendations of the most recent treatment guidelines by the U.S.
Department of Health and Human Services and the International
AIDS Society [17,18].
The results from this study may not be generalizable to other
STI clinics. The patient population characteristics may differ at
other clinics, as MSM comprise a large percentage of testers at the
San Francisco municipal STI clinic. However, the testing
algorithm presented here can be implemented by clinics and
public health departments to enhance HIV surveillance programs.
The strategy of screening for acute HIV infections at STD clinics
has been implemented in a number of U.S. cities. The proportion
of acute infections detected in our study (7.6%) was comparable to
the findings from STD clinics in New York City (8.6%) and higher
than in Baltimore (1.3%) [19,20]. In addition, nearly all of the
acute HIV infection cases detected in New York City were among
MSM, a result similar to our findings.
Our study illustrates how the integration of HIV-1 drug
resistance testing with recent and acute infection screening can
inform existing HIV/STI surveillance and prevention efforts.
Knowledge of transmitted drug resistance prevalence and
correlates of acute and recent infections can help target care and
prevention strategies. Monitoring HIV-1 drug resistance preva-
lence in STI patients may be helpful for determining appropriate
treatment and post-exposure prophylaxis regimens that are active
against viruses circulating in the community.
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